Galanthamine hydrobromide anticholinesterase data

Shire announced that interim results from a Phase II trial of galanthamine show statistically significant slowing of cognitive decline in Alzheimer's patients. In data from 235 patients, clinical improvement was found in cognitive symptoms (p=0.008), as measured by the ADAS-Cog scale. Results were presented at the International Conference on Alzheimer's Disease and Related Disorders in Osaka, Japan.

With the two highest doses tested, the top 20 percent of patients scored changes of 7 points or better on the scale, and 16 percent achieved score changes of 10 points or better. Only one patient on placebo showed a similar outcome. ...